Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter . …After Eli Lilly granted an apparently well-connected 79-year-old patient special access to retatrutide, an unapproved obesity drug, the company confirmed that it will allow other patients to apply for early access, STAT tells us. It marks a striking change in the public posture of the company, which had previously offered little information about the special access program. The initial patient accessed the drug in April via the U.S. Food and Drug Administration’s “compassionate use” program.